1. Home
  2. PCT vs MIRM Comparison

PCT vs MIRM Comparison

Compare PCT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCT
  • MIRM
  • Stock Information
  • Founded
  • PCT 2015
  • MIRM 2018
  • Country
  • PCT United States
  • MIRM United States
  • Employees
  • PCT N/A
  • MIRM N/A
  • Industry
  • PCT Environmental Services
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCT Utilities
  • MIRM Health Care
  • Exchange
  • PCT Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • PCT 2.4B
  • MIRM 1.9B
  • IPO Year
  • PCT N/A
  • MIRM 2019
  • Fundamental
  • Price
  • PCT $12.59
  • MIRM $40.72
  • Analyst Decision
  • PCT Buy
  • MIRM Strong Buy
  • Analyst Count
  • PCT 6
  • MIRM 13
  • Target Price
  • PCT $7.70
  • MIRM $56.23
  • AVG Volume (30 Days)
  • PCT 3.1M
  • MIRM 271.3K
  • Earning Date
  • PCT 11-07-2024
  • MIRM 11-15-2024
  • Dividend Yield
  • PCT N/A
  • MIRM N/A
  • EPS Growth
  • PCT N/A
  • MIRM N/A
  • EPS
  • PCT N/A
  • MIRM N/A
  • Revenue
  • PCT N/A
  • MIRM $264,375,999.00
  • Revenue This Year
  • PCT N/A
  • MIRM $73.07
  • Revenue Next Year
  • PCT $549.70
  • MIRM $27.98
  • P/E Ratio
  • PCT N/A
  • MIRM N/A
  • Revenue Growth
  • PCT N/A
  • MIRM 128.34
  • 52 Week Low
  • PCT $2.39
  • MIRM $23.14
  • 52 Week High
  • PCT $15.58
  • MIRM $45.23
  • Technical
  • Relative Strength Index (RSI)
  • PCT 62.09
  • MIRM 57.14
  • Support Level
  • PCT $12.13
  • MIRM $38.30
  • Resistance Level
  • PCT $13.62
  • MIRM $41.15
  • Average True Range (ATR)
  • PCT 1.02
  • MIRM 1.44
  • MACD
  • PCT -0.06
  • MIRM 0.19
  • Stochastic Oscillator
  • PCT 47.50
  • MIRM 85.67

About PCT PureCycle Technologies Inc. Common stock

PureCycle Technologies Inc holds a license to commercialize the only patented solvent-based purification recycling technology, developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene (PP) into a virgin-like resin. The proprietary process removes color, odor, and other contaminants from recycled feedstock resulting in virgin-like polypropylene suitable for any PP market.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: